Next-generation targeted therapies for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer are associated with improved clinical outcomes, however, tumors develop resistance thus requiring subsequent therapies. Limited data are available on ALK TKI sequencing. The aim of our study was to understand duration of post-brigatinib ALK TKI therapy in the real-world setting.The results indicate that brigatinib has real-world durable clinical effects for patients. Treatment with subsequent TKIs, can still bring benefit to patients after discontinuing brigatinib. More formalized prospective data are needed to establish sequencing recommendations. READ ARTICLE
Annals of Oncology DOI:10.1016/j.annonc.2021.08.1810
Authors: M.O. Jahanzeb, H.M. Lin, Y. Wu, M. Gorritz, C.B. McGuiness, K. Sun, C-C. Chen, P. Zhang, D.R. Camidge
